Evidence map›Paper›PMID 26703953›Full record

ReviewProteomics. Clinical applications2016

Biomarker discovery in mass spectrometry-based urinary proteomics.

Samuel Thomas, Ling Hao, William A Ricke, Lingjun Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Proteomics. Clinical applications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Samuel ThomasMolecular and Environmental Toxicology Center, University of Wisconsin-Madison, Madison, WI, USA.
Ling HaoSchool of Pharmacy, University of Wisconsin-Madison, Madison, WI, USA.
William A RickeMolecular and Environmental Toxicology Center, University of Wisconsin-Madison, Madison, WI, USA.
Lingjun LiMolecular and Environmental Toxicology Center, University of Wisconsin-Madison, Madison, WI, USA.

Funding

Role of Beta-Catenin in Urinary DysfunctionU54DK104310 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI MACOSKA, JILL A., MARKER, PAUL C · 2014 to 2023
$12.8M
Molecular & Environmental Toxicology Pre-& Postdoctoral Training ProgramT32ES007015 · NIEHS · UNIVERSITY OF WISCONSIN-MADISON · PI CHRISTOPHER A BRADFIELD · 1985 to 2026
$11.5M
Estrogen Regulation in BPH and the Lower Urinary TractR01DK093690 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI RICKE, WILLIAM A · 2011 to 2014
$1.3M
Urinary Biomarkers of Lower Urinary Traxct Symptoms (LUTS) in Men P20DK097826 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI BUSHMAN, WADE A · 2012 to 2014
$776k
NIDDK NIH HHS P20 DK097826NIDDK NIH HHS R01 DK093690NIDDK NIH HHS U54 DK104310NIEHS NIH HHS T32 ES007015NIEHS NIH HHS T32-ES007015
6 · The paper itself

Abstract

Urinary proteomics has become one of the most attractive topics in disease biomarker discovery. MS-based proteomic analysis has advanced continuously and emerged as a prominent tool in the field of clinical bioanalysis. However, only few protein biomarkers have made their way to validation and clinical practice. Biomarker discovery is challenged by many clinical and analytical factors including, but not limited to, the complexity of urine and the wide dynamic range of endogenous proteins in the sample. This article highlights promising technologies and strategies in the MS-based biomarker discovery process, including study design, sample preparation, protein quantification, instrumental platforms, and bioinformatics. Different proteomics approaches are discussed, and progresses in maximizing urinary proteome coverage and standardization are emphasized in this review. MS-based urinary proteomics has great potential in the development of noninvasive diagnostic assays in the future, which will require collaborative efforts between analytical scientists, systems biologists, and clinicians.

Indexed as

Acute Kidney InjuryAntigens, NeoplasmAntigens, NuclearBiomarkersBiomarkers, TumorCell Cycle ProteinsFibrinHumansInsulin-Like Growth Factor Binding ProteinsMass SpectrometryNuclear Matrix-Associated ProteinsProteomeProteomicsTissue Inhibitor of Metalloproteinase-2UrinalysisUrinary Bladder NeoplasmsAntigens, NeoplasmAntigens, NuclearBiomarkersBiomarkers, Tumorbladder tumor-associated antigenCell Cycle ProteinsFibrininsulin-like growth factor binding protein-related protein 1Insulin-Like Growth Factor Binding ProteinsNuclear Matrix-Associated ProteinsNUMA1 protein, humanProteomeTIMP2 protein, humanTissue Inhibitor of Metalloproteinase-2BiomarkerMass spectrometryProteomicsUrine

Identifiers

PMID26703953
PMCPMC4888976

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.